Recent developments include Perrigo’s Q3 2026 financial results reporting a net loss, surpassing some earnings metrics, and the announcement of an agreement to divest its infant formula business for up to $175 million.

• Perrigo reported third quarter 2026 results including a net loss and announced an agreement to divest its infant formula business for up to $175 million [N1].
• The company held a Q3 2026 earnings conference call on November 4, 2026 [N3].
• Perrigo’s Q3 2026 earnings surpassed certain earnings metrics despite the net loss [N5].
• The company’s infant formula business divestiture agreement was announced on October 29, 2026 [N7].
• Perrigo’s Q3 2026 results and business developments were covered extensively by Nasdaq [N1][N2][N4][N5][N7].

Perrigo’s ability to maintain strong brand recognition and invest in marketing supports its market presence. The company’s strategic divestiture of the infant formula business may allow focus on core self-care products. Its liquidity position with substantial cash and current assets provides operational flexibility. Successful management of supply chain and regulatory risks could stabilize operations. The company’s ongoing efforts to mitigate cybersecurity and emerging technology risks may enhance operational resilience [N1][S2].

Perrigo faces risks from regulatory changes, including environmental and pharmaceutical regulations that may increase compliance costs and operational complexity. Supply chain disruptions, particularly reliance on single-source suppliers and geopolitical conflicts affecting API supply, pose material risks. Customer concentration risk could impact revenue if relationships deteriorate. Manufacturing concentration increases vulnerability to disruptions. Cybersecurity threats and challenges in leveraging emerging technologies may result in operational and reputational harm. Market shifts in retail and consumer behavior could pressure pricing and sales volume [S1][S2].

Perrigo’s moat is supported by its established brand recognition in the self-care market, strategic supplier relationships, and regulatory compliance capabilities. Its scale in manufacturing and distribution, along with investments in marketing, contribute to competitive positioning. However, the company’s reliance on single-source suppliers and concentrated manufacturing locations introduces operational risks. Regulatory complexity and compliance requirements create barriers to entry for competitors. Customer relationships, including a significant customer concentration, also contribute to its market position [S1].

• Regulatory Compliance Risks: Changes in laws and regulations, including environmental policies like the EU Green Deal and FDA requirements, may increase costs and restrict operations. Non-compliance could lead to fines, penalties, and reputational damage [S1].
• Supply Chain Disruptions: Dependence on single-source suppliers and geopolitical conflicts such as the war in Ukraine and Middle East tensions may disrupt raw material and API supply, affecting manufacturing and delivery [S1].
• Customer Concentration: One customer accounted for 12.9% of net sales in 2025, creating risk if this relationship changes materially or if the customer faces financial difficulties [S1].
• Manufacturing Concentration: Operations concentrated in a few locations increase vulnerability to disruptions from natural disasters, pandemics, or other events [S1].
• Cybersecurity and Emerging Technology Risks: Increasing reliance on complex IT systems exposes the company to cyber-attacks, data breaches, and operational disruptions. Use of AI and other technologies introduces compliance and operational risks [S1].

• Perrigo Company plc is a publicly reporting company with recent SEC filings including a 10-K filed on 2026-02-26 and a 10-Q filed on 2026-11-04 [S1][S2].
• The company reported a net loss of $27.5 million for the quarter ended September 26, 2026, with basic and diluted EPS of -$0.20 [S2].
• As of September 26, 2026, Perrigo had cash and cash equivalents of approximately $432.1 million and current assets of $2.402 billion, with current liabilities of $1.020 billion, resulting in a current ratio of 2.35 and a cash ratio of 0.44 [S2].
• Perrigo announced an agreement to divest its infant formula business to MeridianMade for up to $175 million [N1][N7].
• The company’s Q3 2026 earnings conference call was held on November 4, 2026 [N3].
• Perrigo’s business is subject to extensive government regulation and pricing risks, including compliance with environmental regulations such as the EU Green Deal and FDA requirements, which may increase costs and affect operations [S1].
• Supply chain risks include reliance on single-source suppliers, potential shortages of active pharmaceutical ingredients (API), and disruptions due to geopolitical conflicts such as the war in Ukraine and conflicts in the Middle East [S1].
• The company faces risks from raw material availability and cost volatility, including key ingredients for infant formula derived from raw milk, which are influenced by environmental and policy factors [S1].
• Perrigo’s manufacturing operations are concentrated in a few locations, making it vulnerable to disruptions from natural disasters, pandemics, or other events [S1].
• The company depends on significant customers, with one customer representing 12.9% of consolidated net sales in 2025, creating customer concentration risk [S1].
• Perrigo is exposed to cybersecurity threats and risks related to emerging technologies such as artificial intelligence, which could impact operations and compliance [S1].
• Recent news highlights include Q3 2026 results showing a loss, surpassing some earnings metrics, and the strategic divestiture of the infant formula business [N1][N2][N4][N5][N7].